BMEA—The stock has rebounded to 11% below its closing price on 6/6/24—before the announcement of the FDA clinical hold (#msg-174556998). I do not follow the stock closely, but it seems reasonable for a small deficit to persist relative to the 6/6/24 closing price insofar as the safety problem that caused the clinical hold could conceivably resurface at some point.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.